Author:
Thal Leon J, ,Ferris Steven H,Kirby Louis,Block Gilbert A,Lines Christopher R,Yuen Eric,Assaid Christopher,Nessly Michael L,Norman Barbara A,Baranak Christine C,Reines Scott A
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference51 articles.
1. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL et al (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 289: 2819–2826.
2. Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Zhang Y, Shaffer A et al (2001). Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21: 8198–8209.
3. Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA (2001). Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 161: 152–156.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528.
5. Bresalier RS, Sandler R, Riddell R, Lanas A, Morton D, Reicin A et al (2004). Preliminary Cardiovascular Safety Data from the APPROVe Study, Presented at the annual meeting of the American College of Rheumatology, San Antonio, Texas, October 18. Abstract available at:
http://www.rheumatology.org/annual/press/APPROVesession_annouce.asp
.
Cited by
348 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献